Advancements in AAV Therapy: A Bright Future for Cartilage Regeneration in Arthritis Treatment

Abstract

Arthritis is a debilitating condition affecting millions of individuals worldwide, characterized by joint inflammation and cartilage damage. Current treatment options provide some relief of symptoms, but do not address the underlying cause of the disease and may have significant side effects. Adeno associated virus (AAV)-based gene therapy represents a promising approach to the treatment of arthritis by promoting the regeneration of cartilage and reducing inflammation in the affected joints. AAV vectors can be engineered to deliver genes that promote the production of chondrocytes, the cells that produce cartilage. However, several challenges need to be addressed in order to fully realize the potential of AAV-based gene therapy, including the development of targeted delivery approaches, optimization of vector design, and the need to overcome vector immunity. Additionally, the use of cartilage-specific promoters and combination therapy may help overcome these challenges and advance the development of AAV-based gene therapy for arthritis. Further research in this field has the potential to significantly improve the lives of individuals affected by this debilitating condition.